Navigation Links
Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
Date:4/23/2008

stics of the original human tumor. The Company believes that these Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.

We leverage our preclinical platform to evaluate drug candidates and to develop a portfolio of novel therapeutic candidates through pre-clinical trials. As drugs progress through this early stage of development, the Company plans to sell, partner or license them to pharmaceutical and/or biotechnology companies, as appropriate. The Company also offers its predictive preclinical platform and tumor specific data to physicians for personalized patient care. In the course of this process, this permits us to evaluate oncology drugs for companies by using models that integrate prognostic testing with biomarker discovery.

Champions Biotechnology is dedicated to enhancing preclinical development tools, accelerating development and valuation of oncology drugs, and advancing personalized treatment with a goal to improve the lives of cancer patients globally.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the fiscal year ended April 30, 2007 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
5. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Carrington Completes $8 Million Financing
8. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
9. New Brunswick Scientific Completes Merger Transaction with Eppendorf
10. Kiwa Bio-Tech Completes 1st Stage of Shandong Factory Upgrading
11. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... MORRISTOWN, N.J. , July 28, 2015 /PRNewswire/ ... its second Phase 1 clinical trial with MMI-0100, ... that is being developed for pulmonary disorders characterized ... the United Kingdom , is ... study further evaluating the safety and tolerability of ...
(Date:7/28/2015)... July 28, 2015 CSL Behring ... has accepted for review the company,s Biologics License Application ... (rVIII-SingleChain) for the treatment of hemophilia A. In the ... Hemophilia A is a congenital ... nearly all affected patients are male. People with hemophilia ...
(Date:7/28/2015)... TRIANGLE PARK, N.C., July 28, 2015  United Therapeutics ... financial results for the second quarter ended June 30, ... 300% as compared to the second quarter of ... Roger Jeffs, Ph.D., United Therapeutics, President and Co-Chief ... due to an increase in the number of ...
(Date:7/28/2015)... 28, 2015  Faced with increasing challenges such ... rather than symptomatic, the global healthcare industry today ... capable of curing or significantly changing the course ... look towards regenerative medicine as a viable alternative. ... in human health with the potential to resolve ...
Breaking Biology Technology:Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5
... of Economics and Political Science (LSE), Chatham House, ... Emerging Nanotechnologies (PEN), an initiative of Woodrow Wilson ... Trusts, have been awarded a $587,000 European Commission ... regulating nanotechnologies in the European Union and United ...
... ROCKVILLE, Md., Feb. 6 Novavax, Inc. (Nasdaq:,NVAX) ... Rahul,Singhvi, President and Chief Executive Officer, will be ... 1:15 p.m. on February 12, 2008 at the,Waldorf=Astoria ... an overview of,the company,s strategy, research and development ...
... for P-Capt(R) filters sale in 2008;, - Use of affinity prion adsorbent for plasma-derived products to generate ... M over the next 5 years ... in 2008;,- 10th product approved by the FDA and or the EMEA, contributing to revenue ... growth., MONTREAL, Feb. 6 /PRNewswire-FirstCall/ - ProMetic ...
Cached Biology Technology:European Commission gives grant to investigate transatlantic oversight of nanotech 2European Commission gives grant to investigate transatlantic oversight of nanotech 3ProMetic provides business update - Over $35 million worth of business secured in January 2ProMetic provides business update - Over $35 million worth of business secured in January 3ProMetic provides business update - Over $35 million worth of business secured in January 4
(Date:6/24/2015)... Research and Markets( ... "Huawei Ascend Mate 7 Fingerprint Sensor - ... Huawei,s technological choice for the fingerprint ... Apple,s and Samsung,s one. The Ascend Mate 7 ... Cards, a main actor in capacitive sensing human ...
(Date:6/23/2015)... MINNETONKA, Minn. , June 23, 2015 /PRNewswire/ ... technology company that supports the entire spectrum of ... iMedNet ™ , the company,s ... has been awarded a Silver 2015 Stevie® Award ... the Health Products & Services Website category.  The ...
(Date:6/23/2015)... RALEIGH, N.C. , June 23, 2015 /PRNewswire/ ... technology, today announced the results of a recent ... unmatched accuracy on the wrist during activity. In ... biometric technology was compared along with the Apple ... for accurately measuring heart rate during activity. The ...
Breaking Biology News(10 mins):Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3
... debilitating side effects such as nausea, liver toxicity and a ... to deliver this life-saving therapy to cancer patients ― getting ... invented by Dr. Dan Peer of Tel Aviv University,s Department ... Science and Nano Technology together with Prof. Rimona Margalit of ...
... many cancers. Rui Martinho at the Instituto Gulbenkian de ... Ghent (Belgium) and Bergen (Norway) will use the fruit ... in the test-tube, impact on the way cells divide ... Association for International Cancer Research (AICR), will provide inroads ...
... farmers across the world domesticated wild plants to create ... have been lost, causing problems for anyone studying the ... A team led by Fabiola Parra at the Universidad ... a domesticated cactus, the Gray Ghost Organ Pipe (Stenocereus ...
Cached Biology News:A cluster bomb for cancer care 2Understanding cancer using the fruit fly 2Cactus genes connect modern Mexico to its prehistoric past 2
HSPBP1 Antibody...
... RACE (rapid amplification of cDNA ends) technique ... 5' and 3' cDNA ends. The GeneRacer ... Transcriptase (RT) for improved amplification of the ... mRNA. The RNase H portion of SuperScript ...
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Reactivity: Human...
Biology Products: